Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
FDA approval
Pharma
FDA greenlights RevMed’s pancreatic cancer gamechanger
Following dynamite data that earned a standing ovation at ASCO, RevMed's star Ras inhibitor daraxonrasib has been approved by the FDA.
Darren Incorvaia
Aug 26, 2026 11:30am
Jazz’s Ziihera nets FDA nod in first-line HER2+ stomach cancer
Aug 25, 2026 11:06am
Ultragenyx, after FDA speed bump, lands 1st gene therapy nod
Aug 19, 2026 10:33pm
Pasatru approved by FDA as 2nd drug for rare bone lesion disease
Aug 19, 2026 2:35pm
Celcuity needs facility sign-off to kick off its market launch
Aug 18, 2026 9:26am
BMS bags first FDA approval for CELMoD franchise with Zenbexus
Aug 14, 2026 10:09am
